Mallinckrodt floats $1.6B opioid deal, bankruptcy for specialty generics unit

Mallinckrodt floats $1.6B opioid deal, bankruptcy for specialty generics unit

Source: 
Fierce Pharma
snippet: 

Hamstrung by opioid lawsuits and mounting debt, opioid maker Mallinckrodt has spent the past few months taking a hard look at bankruptcy to help cover its debts. Now, with a massive opioid settlement in the works, Mallinckrodt's specialty generics business will enter court-supervised restructuring to help secure its hefty payments.